[HTML][HTML] Assessing immunogenicity of biologic drugs in inflammatory joint diseases: progress towards personalized medicine
Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but
a substantial proportion of patients either do not respond to treatment or lose response over …
a substantial proportion of patients either do not respond to treatment or lose response over …
[HTML][HTML] Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
JE Gehin, GL Goll, MK Brun, M Jani, N Bolstad… - Biodrugs, 2022 - ncbi.nlm.nih.gov
Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but
a substantial proportion of patients either do not respond to treatment or lose response over …
a substantial proportion of patients either do not respond to treatment or lose response over …
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
JE Gehin, GL Goll, MK Brun, M Jani… - …, 2022 - research.manchester.ac.uk
Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases
(IJDs), but a substantial proportion of patients either do not respond to treatment or lose …
(IJDs), but a substantial proportion of patients either do not respond to treatment or lose …
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.
JE Gehin, GL Goll, MK Brun, M Jani… - … and Gene Therapy, 2022 - europepmc.org
Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but
a substantial proportion of patients either do not respond to treatment or lose response over …
a substantial proportion of patients either do not respond to treatment or lose response over …
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
JE Gehin, GL Goll, MK Brun, M Jani, N Bolstad… - BioDrugs, 2022 - duo.uio.no
Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but
a substantial proportion of patients either do not respond to treatment or lose response over …
a substantial proportion of patients either do not respond to treatment or lose response over …
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
JE Gehin, GL Goll, MK Brun, M Jani, N Bolstad… - …, 2022 - search.proquest.com
Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but
a substantial proportion of patients either do not respond to treatment or lose response over …
a substantial proportion of patients either do not respond to treatment or lose response over …
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
JE Gehin, GL Goll, MK Brun, M Jani… - … and gene therapy, 2022 - pubmed.ncbi.nlm.nih.gov
Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but
a substantial proportion of patients either do not respond to treatment or lose response over …
a substantial proportion of patients either do not respond to treatment or lose response over …